Overview

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection

Status:
Completed
Trial end date:
2021-03-18
Target enrollment:
Participant gender:
Summary
To compare the efficacy of Helicobacter pylori (HP) eradication with vonoprazan dual and triple therapy regimens versus lansoprazole triple therapy regimen in participants with HP infection, excluding participants who had a clarithromycin or amoxicillin resistant strain of HP at baseline.
Phase:
Phase 3
Details
Lead Sponsor:
Phathom Pharmaceuticals, Inc.
Treatments:
Amoxicillin
Clarithromycin
Dexlansoprazole
Lansoprazole